Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115797 | 0.90 | PTGDR2 (0.40) | PTGDR2MAPTNPSR1TP53L3MBTL1 | |
| SCHEMBL5122394 | 0.87 | PTGDR2 (0.46) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5107864 | 0.86 | NPSR1 (0.43) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5121874 | 0.86 | PTGDR2 (0.41) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5121197 | 0.86 | PTGDR2 (0.40) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5114644 | 0.85 | PTGDR2 (0.38) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5106845 | 0.85 | PTGDR2 (0.41) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5121561 | 0.85 | PTGDR2 (0.46) | PTGDR2MEN1KMT2ATP53L3MBTL1 | |
| SCHEMBL5115798 | 0.85 | PTGDR2 (0.40) | PTGDR2LMNAMAPTNPSR1MEN1 | |
| SCHEMBL5510465 | 0.84 | PTGDR2 (0.44) | PTGDR2LMNAMAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 12/4885LMNA 4724/4885MAPT 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.